Failure to ubiquitinate c-Met leads to hyperactivation of mTOR signaling in a mouse model of autosomal dominant polycystic kidney disease
Open accessThe DOI matches its Crossref record; 67 of the 67 references it cites were found in a registry or an index.
Abstract
Autosomal dominant polycystic kidney disease (ADPKD) is a common inherited disorder that is caused by mutations at two loci, polycystin 1 (PKD1) and polycystin 2 (PKD2). It is characterized by the formation of multiple cysts in the kidneys that can lead to chronic renal failure. Previous studies have suggested a role for hyperactivation of mammalian target of rapamycin (mTOR) in cystogenesis, but the etiology of mTOR hyperactivation has not been fully elucidated. In this report we have shown that mTOR is hyperactivated in Pkd1-null mouse cells due to failure of the HGF receptor c-Met to be properly ubiquitinated and subsequently degraded after stimulation by HGF. In Pkd1-null cells, Casitas B-lineage lymphoma (c-Cbl), an E3-ubiquitin ligase for c-Met, was sequestered in the Golgi apparatus with α₃β₁ integrin, resulting in the inability to ubiquitinate c-Met. Treatment of mouse Pkd1-null cystic kidneys in organ culture with a c-Met pharmacological inhibitor resulted in inhibition of mTOR activity and blocked cystogenesis in this mouse model of ADPKD. We therefore suggest that blockade of c-Met is a potential novel therapeutic approach to the treatment of ADPKD.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“transplantation to reconstitute the brain with wild-type microglia reverses somatic phenotypes, neuropathological changes, and behavioural abnormalities in two mouse models of ASD — MeCP2−/y model of Rett syndrome232 and the MIA model132.”
From Immune mediators in the brain and peripheral tissues in autism spectrum disorder (2015) · cites this paper as [232]
Citations
Cites
PKD2 , a Gene for Polycystic Kidney Disease That Encodes an Integral Membrane Protein
Mochizuki, T., Wu, G., Hayashi, T., Xenophontos, S. L., Veldhuisen, B., Saris, J. J., Reynolds, D. M., Cai, Y., Gabow, P. A., Pierides, A., et al. (1996) · Science · doi:10.1126/science.272.5266.1339 · Cited by 1,406
Yoder, B. K., Hou, X., & Guay-Woodford, L. M. (2002) · Journal of the American Society of Nephrology · doi:10.1097/01.asn.0000029587.47950.25 · Cited by 935
Expression of the c-ret proto-oncogene during mouse embryogenesis
Pachnis, V., Mankoo, B., & Costantini, F. (1993) · Development · doi:10.1242/dev.119.4.1005 · Cited by 837
Shillingford, J. M., Murcia, N. S., Larson, C. H., Low, S. H., Hedgepeth, R., Brown, N., Flask, C. A., Novick, A. C., Goldfarb, D. A., Kramer-Zucker, A., et al. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0509694103 · Cited by 808
Alpha 3 beta 1 integrin has a crucial role in kidney and lung organogenesis
Kreidberg, J. A., Donovan, M. J., Goldstein, S. L., Rennke, H., Shepherd, K., Jones, R. C., & Jaenisch, R. (1996) · Development · doi:10.1242/dev.122.11.3537 · Cited by 723
Self-citationBalch, W. E., Dunphy, W. G., Braell, W. A., & Rothman, J. E. (1984) · Cell · doi:10.1016/0092-8674(84)90019-9 · Cited by 696
Defective planar cell polarity in polycystic kidney disease
Fischer, E., Legue, E., Doyen, A., Nato, F., Nicolas, J.-F., Torres, V., Yaniv, M., & Pontoglio, M. (2006) · Nature Genetics · doi:10.1038/ng1701 · Cited by 537
Loss of Fat4 disrupts PCP signaling and oriented cell division and leads to cystic kidney disease
Saburi, S., Hester, I., Fischer, E., Pontoglio, M., Eremina, V., Gessler, M., Quaggin, S. E., Harrison, R., Mount, R., & McNeill, H. (2008) · Nature Genetics · doi:10.1038/ng.179 · Cited by 525
Follit, J. A., Tuft, R. A., Fogarty, K. E., & Pazour, G. J. (2006) · Molecular Biology of the Cell · doi:10.1091/mbc.e06-02-0133 · Cited by 498
Nauli, S. M., Kawanabe, Y., Kaminski, J. J., Pearce, W. J., Ingber, D. E., & Zhou, J. (2008) · Circulation · doi:10.1161/circulationaha.107.710111 · Cited by 466
Self-citation
Research works printed but not linked: 5
- Takayama, 1997, Lab Invest., 77, 131
- Lanoix, 1996, Oncogene., 13, 1153
- Ehara, 1994, Am J Pathol., 144, 612
- Carone, 1993, Lab Invest., 68, 413
- Girod, 1980, C R Seances Acad Sci D., 290, 711
Cited by
Immune mediators in the brain and peripheral tissues in autism spectrum disorder
Estes, M. L., & McAllister, A. K. (2015) · Nature Reviews Neuroscience · doi:10.1038/nrn3978 · Cited by 514
Signaling through the Primary Cilium
Wheway, G., Nazlamova, L., & Hancock, J. T. (2018) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2018.00008 · Cited by 483
“Other studies in the Pkd1 mouse showed that mTOR hyperactivation was due to a failure of ubiquitination of c-met, a hepatocyte growth factor receptor (Qin et al., 2010).”
BackgroundPyrimethamine inhibits adult polycystic kidney disease by modulating STAT signaling pathways
Takakura, A., Nelson, E. A., Haque, N., Humphreys, B. D., Zandi-Nejad, K., Frank, D. A., & Zhou, J. (2011) · Human Molecular Genetics · doi:10.1093/hmg/ddr338 · Cited by 143
Self-citationChristensen, S. T., Morthorst, S. K., Mogensen, J. B., & Pedersen, L. B. (2017) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a028167 · Cited by 125
“Polycystin signaling may also involve interaction with another RTK, c-Met, which was shown in mouse kidney cells to rely on polycystin 1 for appropriate ubiquitylation and signaling down-regulation in response to stimulation with the c-Met ligand, hepatocyte growth factor (HGF) (Qin et al. 2010).”
BackgroundMuto, Y., Dixon, E. E., Yoshimura, Y., Wu, H., Omachi, K., Ledru, N., Wilson, P. C., King, A. J., Olson, N. E., Gunawan, M. G., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-34255-z · Cited by 131
Rheb/mTORC1 Signaling Promotes Kidney Fibroblast Activation and Fibrosis
Jiang, L., Xu, L., Mao, J., Li, J., Fang, L., Zhou, Y., Liu, W., He, W., Zhao, A. Z., Yang, J., et al. (2013) · Journal of the American Society of Nephrology · doi:10.1681/asn.2012050476 · Cited by 92
mTOR signaling in polycystic kidney disease
Ibraghimov‐Beskrovnaya, O., & Natoli, T. A. (2011) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2011.06.003 · Cited by 97
Pandey, P., Qin, S., Ho, J., Zhou, J., & Kreidberg, J. A. (2011) · BMC Systems Biology · doi:10.1186/1752-0509-5-56 · Cited by 91
“Indeed, in Pkd1 mice, defective glycosylation of protein has been observed, that may have important implications for ADPKD [62,63].”
BackgroundSelf-citationExtracellular matrix, integrins, and focal adhesion signaling in polycystic kidney disease
Zhang, Y., Reif, G. A., & Wallace, D. P. (2020) · Cellular Signalling · doi:10.1016/j.cellsig.2020.109646 · Cited by 81
“This group later showed that in Pkd1−/− cells, α3β1 integrin was mostly sequestered in the Golgi, along with the E3 ubiquitin ligase c-Cbl and there was subsequent overexpression of c-MET, a receptor tyrosine kinase target of c-Cbl [76].”
BackgroundSu, X., Driscoll, K., Yao, G., Raed, A., Wu, M., Beales, P. L., & Zhou, J. (2014) · Human Molecular Genetics · doi:10.1093/hmg/ddu267 · Cited by 75
Self-citationCbl-independent degradation of Met: ways to avoid agonism of bivalent Met-targeting antibody
Lee, J. M., Kim, B., Lee, S. B., Jeong, Y., Oh, Y. M., Song, Y.-J., Jung, S. H., Choi, J., Lee, S., Cheong, K. H., et al. (2012) · Oncogene · doi:10.1038/onc.2012.551 · Cited by 75
Molecular pathways involved in injury-repair and ADPKD progression
Formica, C., & Peters, D. J. M. (2020) · Cellular Signalling · doi:10.1016/j.cellsig.2020.109648 · Cited by 73
Xu, Y., Kuppe, C., Perales-Patón, J., Hayat, S., Kranz, J., Abdallah, A. T., Nagai, J. S., Li, Z., Peisker, F., Saritas, T., et al. (2022) · Nature Genetics · doi:10.1038/s41588-022-01202-z · Cited by 73
Qin, S., Taglienti, M. E., Cai, L., Zhou, J., & Kreidberg, J. A. (2012) · Journal of the American Society of Nephrology · doi:10.1681/asn.2011030277 · Cited by 71
Self-citationRegulation of STATs by polycystin-1 and their role in polycystic kidney disease
Weimbs, T., Olsan, E. E., & Talbot, J. J. (2013) · JAK-STAT · doi:10.4161/jkst.23650 · Cited by 74
Met degradation: more than one stone to shoot a receptor down
Lefebvre, J., Ancot, F., Leroy, C., Muharram, G., Lemière, A., & Tulasne, D. (2012) · The FASEB Journal · doi:10.1096/fj.11-197723 · Cited by 74
“Finally, treatment with pharmacological inhibitor directed against the Met kinase results in inhibition of multiple cyst formation in kidney organ culture and in the mouse model of ADPKD (80).”
BackgroundLin, Y., Wang, Y., Yang, J. C., Yu, C., Wu, S., Shih, J., & Yang, P. (2014) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000326 · Cited by 63
“In a mouse model of ADPKD, the inhibition of c-Met by Su-11274 and PHA-665752 lead to the inhibition of cystogenesis.(15) It remains doubtful if crizotinib can have the opposite effect on renal cyst formation.”
MethodPeriostin promotes renal cyst growth and interstitial fibrosis in polycystic kidney disease
Wallace, D. P., White, C., Savinkova, L., Nivens, E., Reif, G. A., Pinto, C. S., Raman, A., Parnell, S. C., Conway, S. J., & Fields, T. A. (2013) · Kidney International · doi:10.1038/ki.2013.488 · Cited by 60
Mammalian target of rapamycin and the kidney. II. Pathophysiology and therapeutic implications
Lieberthal, W., & Levine, J. S. (2012) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00015.2012 · Cited by 57
“Some animal models of PKD also show evidence of increased activity of mTORC2, as indicated by increased phosphorylation of Akt at Ser(473) in cystic epithelial cells (4, 122, 140, 170).”
BackgroundPhysiologic mechanisms underlying polycystic kidney disease
Boletta, A., & Caplan, M. J. (2025) · Physiological Reviews · doi:10.1152/physrev.00018.2024 · Cited by 56
Molecular and cellular pathogenesis of autosomal dominant polycystic kidney disease
Bastos, A. P., & Onuchic², L. F. (2011) · Brazilian Journal of Medical and Biological Research · doi:10.1590/s0100-879x2011007500068 · Cited by 58
Regulation of ciliary membrane protein trafficking and signalling by kinesin motor proteins
Morthorst, S. K., Christensen, S. T., & Pedersen, L. B. (2018) · The FEBS Journal · doi:10.1111/febs.14583 · Cited by 49
The Future of Polycystic Kidney Disease Research—As Seen By the 12 Kaplan Awardees
Antignac, C., Calvet, J. P., Germino, G. G., Grantham, J. J., Guay‐Woodford, L. M., Harris, P. C., Hildebrandt, F., Peters, D. J. M., Somlo, S., Torres, V. E., et al. (2015) · Journal of the American Society of Nephrology · doi:10.1681/asn.2014121192 · Cited by 49
Self-citationMalekshahabi, T., Rad, N. K., Serra, A. L., & Moghadasali, R. (2019) · Journal of Cellular Physiology · doi:10.1002/jcp.28094 · Cited by 47
Delitto, D., Zhang, D., Han, S., Black, B. S., Knowlton, A. E., Vlada, A. C., Sarosi, G. A., Behrns, K. E., Thomas, R. M., Lu, X., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1256 · Cited by 40
“Control of c-Met levels in this manner has been demonstrated previously through sequestration of the E3-ubiquitin ligase responsible for the ubiquitination of c-Met in the Golgi apparatus (40).”
BackgroundNephronophthisis-Pathobiology and Molecular Pathogenesis of a Rare Kidney Genetic Disease
Gupta, S., Ozimek-Kulik, J. E., & Phillips, J. K. (2021) · Genes · doi:10.3390/genes12111762 · Cited by 38
The regulatory 1α subunit of protein kinase A modulates renal cystogenesis
Ye, H., Wang, X., Constans, M., Sussman, C. R., Chebib, F. T., Irazabal, M. V., Young, W. F., Harris, P. C., Kirschner, L. S., & Torres, V. E. (2017) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00119.2017 · Cited by 36
Molecular Mechanisms of Epigenetic Regulation, Inflammation, and Cell Death in ADPKD
Agborbesong, E., Li, L. X., Li, L., & Li, X. (2022) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2022.922428 · Cited by 35
“Treatment with CPX-O in PKD mice inhibited cystogenesis as seen by the decrease of cyst index and cystic cell proliferation, and the improvement of renal function, suggesting that CPX-O may delay cyst growth through affecting ferroptosis process in Pkd1 mutant mice (Radadiya et al., 2021).”
BackgroundSubramanian, B., Ko, W.-C. C., Yadav, V., DesRochers, T. M., Perrone, R. D., Zhou, J., & Kaplan, D. L. (2012) · Biomaterials · doi:10.1016/j.biomaterials.2012.08.020 · Cited by 32
“Earlier evidence at least from Pkd1 / kidneys has shown that increased distribution is localized to both membrane and cytoplasmic regions [43].”
Self-citationLuo, X., Deng, L., Lamsal, L. P., Xu, W., Xiang, C., & Cheng, L. (2015) · Cellular Physiology and Biochemistry · doi:10.1159/000369687 · Cited by 32
STAT3 signaling in polycystic kidney disease
Weimbs, T., & Talbot, J. J. (2013) · Drug Discovery Today Disease Mechanisms · doi:10.1016/j.ddmec.2013.03.001 · Cited by 36
USP8 modulates ubiquitination of LRIG1 for Met degradation
Oh, Y. M., Lee, S. B., Choi, J., Suh, H., Shim, S., Song, Y.-J., Kim, B., Lee, J. M., Oh, S. J., Jeong, Y., et al. (2014) · Scientific Reports · doi:10.1038/srep04980 · Cited by 30
Primary Cilia in Cystic Kidney Disease
Avasthi, P. P., Maser, R. L., & Tran, P. V. (2017) · Results and problems in cell differentiation · doi:10.1007/978-3-319-51436-9_11 · Cited by 33
“Lack of ubiquitination of the hepatocyte growth factor (HGF) receptor, c-Met, also activates mTOR signaling in a PKD mouse model, and administration of a c-Met inhibitor attenuated renal cystogenesis in Pkd1-null mutant embryos (Qin et al. 2010).”
BackgroundTang, Z. (2011) · Molecular Medicine Reports · doi:10.3892/mmr.2011.503 · Cited by 28
Glycosphingolipid metabolism and polycystic kidney disease
Natoli, T. A., Modur, V., & Ibraghimov‐Beskrovnaya, O. (2020) · Cellular Signalling · doi:10.1016/j.cellsig.2020.109526 · Cited by 27
Mammalian target of rapamycin inhibition in polycystic kidney disease: From bench to bedside
Kim, H., & Edelstein, C. L. (2012) · Kidney Research and Clinical Practice · doi:10.1016/j.krcp.2012.07.002 · Cited by 28
“Slowing of progression of PKD by 2-hydroxyestradiol in male Han:SPRD rats is associated with downregulation of p21 and mTOR expression [37]. mTOR is hyperactivated in Pkd1 null mice due to failure of the hepatocyte growth factor (HGF) receptor c-Met to be properly ubiquinated and subsequently degraded after stimulatio…”
BackgroundLiu, Z., Cai, Y., Yang, Y. Z., Li, A., Bi, R., Wang, L., Shen, X., Wang, W., Jia, Y., Yu, B., et al. (2018) · The Journal of Pathology · doi:10.1002/path.5108 · Cited by 22
“We intraperitoneally treated the mice every other day with the vehicle (DMSO), with crizotinib and ricolinostat (Selleck Chemicals, Houston, TX, USA; 50 mg/kg body weight) through daily oral gavage [22,33], or with the ricolinostat/crizotinib combination for 18 days.”
BackgroundMethodExperimental Therapies and Ongoing Clinical Trials to Slow Down Progression of ADPKD
Irazabal, M. V., & Torres, V. E. (2013) · Current Hypertension Reviews · doi:10.2174/1573402111309010008 · Cited by 23
“Hepatocyte growth factor (HGF) and c-Met (HGF receptor) are overexpressed by cyst-lining cells in kidneys from individuals with PKD or acquired cystic disease [137].”
BackgroundPolycystin-1 regulates the stability and ubiquitination of transcription factor Jade-1
Foy, R. L., Chitalia, V. C., Panchenko, M. V., Zeng, L., Lopez, D., Lee, J. W., Rana, S. V., Boletta, A., Qian, F., Tsiokas, L., et al. (2012) · Human Molecular Genetics · doi:10.1093/hmg/dds391 · Cited by 20
Ma, X., Nie, Y.-Y., Xie, S., Zheng, H., Tong, Y., Wang, Y., Yan, T., Meng, X., Cao, J., Tang, W., et al. (2023) · Experimental Hematology and Oncology · doi:10.1186/s40164-023-00393-3 · Cited by 20
Mammalian target of rapamycin complex 1 activation in podocytes promotes cellular crescent formation
Mao, J., Zeng, Z., Xu, Z., Li, J., Jiang, L., Fang, Y., Xu, X., Hu, Z., He, W., Yang, J., et al. (2014) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00018.2014 · Cited by 18
He, J., Zhang, S., Qiu, Z., Li, X., Huang, H., Jin, W. W., Xu, Y. C., Shao, G., Wang, L., Meng, J., et al. (2021) · Journal of the American Society of Nephrology · doi:10.1681/asn.2020111560 · Cited by 16
“both demonstrate beneficial effects in blocking cyst growth in animals.(30,31) All of this evidence suggests that FAKmay serve as a crucial”
BackgroundAbnormal glycosylation in Joubert syndrome type 10
Kane, M. S., Davids, M., Bond, M. R., Adams, C. J., Grout, M. E., Phelps, I. G., O’Day, D. R., Dempsey, J. C., Li, X., Golas, G. A., et al. (2017) · Cilia · doi:10.1186/s13630-017-0048-6 · Cited by 16
Stayner, C., Shields, J. A., Slobbe, L. J., Shillingford, J. M., Weimbs, T., & Eccles, M. R. (2012) · Nephrology · doi:10.1111/j.1440-1797.2012.01639.x · Cited by 14
“However, the future use of mTOR inhibitors in treating ADPKD, particularly for early and/or longer-term administration, most likely depends on a new generation of drugs that target the mTOR pathway more specifically, and/or at different locations.(28,29) The data shown in Figures 3–5 suggest that although Pax2, which…”
BackgroundDAB2IP modulates primary cilia formation associated with renal tumorigenesis
Lin, C., Dang, A., Hernández, E., & Hsieh, J. (2020) · Neoplasia · doi:10.1016/j.neo.2020.12.002 · Cited by 10
Friedrich, S., Müller, H., Riesterer, C., Schüller, H., Friedrich, K., Wörner, C. L., Busch, T., Viau, A., Kuehn, E. W., Köttgen, M., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-94442-8 · Cited by 9
Yasinoglu, S. A., Kuipers, T. B., Suidgeest, E., van der Weerd, L., Mei, H., Baelde, H. J., & Peters, D. J. M. (2023) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2023.166987 · Cited by 7
Brownjohn, P. W., Zoufir, A., O’Donovan, D. J., Sudhahar, S., Syme, A., Huckvale, R., Porter, J. R., Bange, H., Brennan, J., & Thompson, N. T. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1397864 · Cited by 8
Multicystic kidney disease: A complication of crizotinib
Souteyrand, P., Burtey, S., & Barlési, F. (2014) · Diagnostic and Interventional Imaging · doi:10.1016/j.diii.2014.11.017 · Cited by 7
Role of PKR in the Inhibition of Proliferation and Translation by Polycystin-1
Tang, Y., Shi, G., Yang, J., Zheng, W., Tang, J., Chen, X., Yang, J., & Wang, Z. (2019) · BioMed Research International · doi:10.1155/2019/5320747 · Cited by 7
Zhang, A. F., Wu, S.-L., Jung, Y., Qin, S., Hancock, W. S., & Kreidberg, J. A. (2014) · Journal of Proteome Research · doi:10.1021/pr5009702 · Cited by 8
Self-citationc‐Cbl induced podocin ubiquitination contributes to the podocytes injury in diabetic nephropathy
Liang, L., He, M., Zhou, P., Pan, S., Chen, J., Lv, L., Hu, M., Zhou, S., Liu, D., & Liu, Z. (2024) · The FASEB Journal · doi:10.1096/fj.202400356r · Cited by 5
Zhang, Y., Plansinis, M., Peak, S., Weber, E., Wei, A., Xu, Y., Ross, M., Leagjeld, A., Wallace, D. P., & Zhang, Y. (2025) · Cellular Signalling · doi:10.1016/j.cellsig.2025.111749 · Cited by 5
Liu, F., Li, X., Li, Q., Gu, J., Shi, Q., Song, J., Jiao, N., & Mao, J. (2025) · Kidney Diseases · doi:10.1159/000545663 · Cited by 5
Preval, K. M., Smith, A. O., & Pazour, G. J. (2025) · Journal of Cellular Signaling · doi:10.33696/signaling.6.144 · Cited by 4
“Under normal conditions, RTK signaling is regulated by ligand-induced degradation to prevent sustained activation [101].”
Ikeda, K., Kusaba, T., Tomita, A., Uehara-Watanabe, N., Ida, T., Kitani, T., YAMASHITA, N., Uehara, M., Matoba, S., Yamada, T., et al. (2020) · The Nephron journals/Nephron journals · doi:10.1159/000509419 · Cited by 4
Diedrich, B., & Dengjel, J. (2017) · Cell and Tissue Research · doi:10.1007/s00441-017-2617-9 · Cited by 5
Schimmel, M. F., Bourgeois, B. C., Spindt, A. K., Patel, S. A., Chin, T., Cornick, G. E., Liu, Y., & Weimbs, T. (2025) · Cell Reports Medicine · doi:10.1016/j.xcrm.2025.102335 · Cited by 3
“19,20 cMET is overexpressed in renal cysts and present on the apical membrane 19,20 where it may be readily activated by its ligand, 21 the hepatocyte growth factor (HGF).”
Maser, R. L., Magenheimer, B. S., & Calvet, J. P. (2019) · Methods in cell biology · doi:10.1016/bs.mcb.2019.04.018 · Cited by 5
Targeting TRPM3 as a potential therapeutic approach for autosomal dominant polycystic kidney disease
Gül, H., & Davies, J. A. (2025) · Scientific Reports · doi:10.1038/s41598-025-89200-z · Cited by 2
“We chose an assay system based on cultured mouse embryonic kidney rudiments, that has been well-characterized and used by several laboratories in the past 12,24–29 .”
Cyclin-dependent kinase 4 drives cystic kidney disease in the absence of mTORC1 signaling activity
Grahammer, F., Dumoulin, B., Gulieva, R. E., Wu, H., Xu, Y., Sulaimanov, N., Arnold, F., Sandner, L., Cordts, T., Todkar, A., et al. (2024) · Kidney International · doi:10.1016/j.kint.2024.08.021 · Cited by 2
A small molecule fibrokinase inhibitor in a model of fibropolycystic hepatorenal disease
Paka, P., Huang, B. L., Duan, B., Li, J., Zhou, P., Paka, L., Yamin, M., Friedman, S. L., Goldberg, I. D., & Narayan, P. (2018) · World Journal of Nephrology · doi:10.5527/wjn.v7.i5.96 · Cited by 2
Kim, S., Kim, M.-H., Ko, B.-K., Kim, K.-M., Wang, N., Jo, S.-M., Go, H., Park, E., & Lee, C.-W. (2026) · Cell Death and Disease · doi:10.1038/s41419-026-08479-6 · Cited by 1
Identification of Factors Regulating MET Receptor Endocytosis by High-Throughput siRNA Screening
Gažiová, I., Davey, R. A., & Elferink, L. A. (2014) · Methods in molecular biology · doi:10.1007/978-1-4939-2309-0_26 · Cited by 1
Kim, H., & Edelstein, C. L. (2012) · Kidney Research and Clinical Practice · doi:10.1016/j.krcp.2012.07.001
Zhang, A. (2015) · Digital Repository Service (Northeastern University) · doi:10.17760/d20195696
The application of LC/MS to exploration of potential biomarkers for disease and protein therapeutics
Liu, Y. (2017) · Digital Repository Service (Northeastern University) · doi:10.17760/d20252003
Identification d'agents thérapeutiques pour les patients atteints de néphronophtise
García, H. (2020) · theses.fr (ABES) · doi:10.70675/6f28e0f3zb345z4503zb87azd051790e51af
Ma, X.-L., Nie, Y.-Y., Xie, S.-H., Zheng, H., Tong, Y., Wang, Y.-C., Yan, T.-Q., Meng, X., Cao, J.-Z., Tang, W.-G., et al. (2023) · Figshare · doi:10.6084/m9.figshare.22639653
Ma, X.-L., Nie, Y.-Y., Xie, S.-H., Zheng, H., Tong, Y., Wang, Y.-C., Yan, T.-Q., Meng, X., Cao, J.-Z., Tang, W.-G., et al. (2023) · Figshare · doi:10.6084/m9.figshare.22639650
Genomic and epigenomic landscape of ADPKD: towards precision diagnostics and tailored treatments
Salybekov, A. A., Kinzhebay, A., Hidaka, S., & Kobayashi, S. (2026) · Frontiers in Epigenetics and Epigenomics · doi:10.3389/freae.2026.1699528 · Cited by 1
“The JAK-STAT pathway is influenced by polycystins, with PC1 activating JAK2 to phosphorylate STAT proteins, particularly STAT1 and STAT3, which then regulate gene transcription (Qin et al., 2010).”
Etude des propriétés apoptotiques du récepteur tyrosine kinase Met
Jonathan, L. (2011) · theses.fr (ABES) · doi:10.70675/2ad09e65z6cdcz4bb4z9625z10b4cc3b5308
Metadata
- Authors
- Qin, S., Taglienti, M., Nauli, S. M., Contrino, L., Takakura, A., Zhou, J., & Kreidberg, J. A.
- Affiliations
- Boston Children's Hospital (US)
- Brigham and Women's Hospital (US)
- Venue
- Journal of Clinical Investigation
- Published
- 2010-10-01
- Volume
- 120
- Issue
- 10
- Pages
- 3617-3628
- ISSN
- 0021-9738 (ISSN-L)
- PMC
- PMC2947217
- OpenAlex
- W2055349890
- Cited by
- 70
- References
- 67
- Citations by year
- 2026: 2 · 2025: 6 · 2024: 3 · 2023: 4 · 2022: 3 · 2021: 3 · 2020: 5 · 2019: 3 · 2018: 4 · 2017: 5 · 2016: 1 · 2015: 5 · 2014: 7 · 2013: 5 · 2012: 9
- FWCI
- 3.42
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Journal of Clinical Investigation (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Chapman University Digital Commons (Chapman University) (submittedVersion)
- Funders
- American Heart Association
- PKD Foundation
- National Institutes of Health (DK51050)
- National Institute of Diabetes and Digestive and Kidney Diseases (DK50118-01, DK 40703, P50DK074030, DK 51050, R01DK050118, DK074030, R37DK051050, R01DK051050, R01DK040703)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetic and Kidney Cyst Diseases
- Health Sciences › Medicine › Genetics (clinical) › Tuberous Sclerosis Complex Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Autophagy in Disease and Therapy
- Keywords
- autosomal dominant polycystic kidney disease, c-Met, mTOR signaling, ubiquitination, polycystin-1, polycystin-2, c-Cbl, E3 ubiquitin ligase, HGF receptor, alpha3beta1 integrin, Golgi apparatus, cyst formation, c-Met inhibitor, therapeutic target
- MeSH terms
- Animals, Cell Line, Cilia, Disease Models, Animal, Glycosylation, Golgi Apparatus, Morphogenesis, Signal Transduction, Polycystic Kidney, Autosomal Dominant, Protein Serine-Threonine Kinases, Proto-Oncogene Proteins c-met, Integrin alpha3beta1, Intracellular Signaling Peptides and Proteins, TRPP Cation Channels, Proto-Oncogene Proteins c-cbl, Mice, Ubiquitination, TOR Serine-Threonine Kinases
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.